Literature DB >> 9721882

Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors.

D C Chung1, S B Brown, F Graeme-Cook, L G Tillotson, A L Warshaw, R T Jensen, A Arnold.   

Abstract

Only two tumor suppressor gene loci, one on 3p25 and the MEN1 gene on 11q13, have thus far been implicated in the pathogenesis of sporadic human pancreatic endocrine tumors (PETs). A genome-wide allelotyping study of 28 human PETs was undertaken to identify other potential tumor suppressor gene loci. In addition to those on chromosomes 3p and 11q, frequent allelic deletions were identified on 3q (32%), 11p (36%), 16p (36%), and 22q (29%). Finer deletion mapping studies localized the smallest regions of common deletion to 3q27, 11p13, and 16p12.3-13.11. Potential candidate genes at these loci include WT1 (11p13), TSC2 (16p13), and NF2 (22q12), but no known tumor suppressor gene localizes to 3q27. The mean fractional allelic loss among these human PETs is 0.126, and no correlation was observed between allelic loss and clinical parameters, including age, sex, hormonal subtype, and disease stage. These findings highlight novel locations of tumor suppressor gene loci that contribute to the pathogenesis of human PETs, and several of these on 3p, 3q, and 22q are syntenic with loci on mouse chromosomes 9 and 16 that are implicated in a murine transgenic model of PETs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721882

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization.

Authors:  E J Speel; J Richter; H Moch; C Egenter; P Saremaslani; K Rütimann; J Zhao; A Barghorn; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Detailed deletion mapping of loss of heterozygosity on 22q13 in sporadic colorectal cancer.

Authors:  Hai-Tao Zheng; Zhi-Hai Peng; Chong-Zhi Zhou; Da-Peng Li; Zhao-Wen Wang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

4.  Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q.

Authors:  P S Moore; G Zamboni; A Brighenti; D Lissandrini; D Antonello; P Capelli; G Rigaud; M Falconi; A Scarpa
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

5.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

6.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

7.  Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis.

Authors:  Evan D Rosen; Rohit N Kulkarni; Pasha Sarraf; Umut Ozcan; Terumasa Okada; Chung-Hsin Hsu; Daniel Eisenman; Mark A Magnuson; Frank J Gonzalez; C Ronald Kahn; Bruce M Spiegelman
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.

Authors:  Michael G House; James G Herman; Ming Zhou Guo; Craig M Hooker; Richard D Schulick; Keith D Lillemoe; John L Cameron; Ralph H Hruban; Anirban Maitra; Charles J Yeo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

9.  Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.

Authors:  Xu Han; Yuan Ji; Jing Zhao; Xuefeng Xu; Wenhui Lou
Journal:  Tumour Biol       Date:  2013-05-19

10.  Prognostic significance of MTOR pathway component expression in neuroendocrine tumors.

Authors:  Zhi Rong Qian; Monica Ter-Minassian; Jennifer A Chan; Yu Imamura; Susanne M Hooshmand; Aya Kuchiba; Teppei Morikawa; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Xihong Lin; David C Christiani; Charles S Fuchs; Shuji Ogino; Matthew H Kulke
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.